On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024
Further strengthened balance sheet with closing of
Cash runway into second half of 2026 to fund anticipated interim readout of KRRO-110 in the second half of 2025 and FIH study completion in 2026
Appointed
"Korro’s first quarter performance reflects significant progress on all fronts in a short period of time. Today, we are excited to announce the addition of Dr.
Pipeline and Business Updates:
- Strengthened cash position with a
$70.0 million PIPE. InApril 2024 , Korro announced a PIPE of approximately$70.0 million with participation from new and existing investors. The PIPE was led by funds affiliated withDeep Track Capital , with participation fromAtlas Venture , Blue Owl Healthcare Opportunities, NEA,Rock Springs Capital ,Tri Locum Partners , and other leading healthcare investors. - Progressed KRRO-110 towards a regulatory filing. KRRO-110 is the first RNA editing oligonucleotide product candidate from Korro’s proprietary RNA editing platform OPERA™. KRRO-110 is designed to co-opt an endogenous enzyme, Adenosine Deaminase Acting on RNA (ADAR), to edit the “A” variant on SERPINA1 RNA, repair an amino acid codon, and restore secretion of normal alpha-1 antitrypsin (AAT) protein. This repair of the endogenous protein has the potential to clear protein aggregates from within liver cells to create a potentially clinically differentiated benefit for liver function and to preserve lung function by providing an adequate amount of normal AAT protein.
- Appointed Dr.
Kemi Olugemo as Chief Medical Officer.Dr. Olugemo brings more than 10 years of industry experience focused on clinical development and regulatory strategy. She joins Korro after serving as VP & Therapeutic Head,Neurology Global Clinical Development at Ultragenyx Pharmaceutical. In this role, she directed and oversaw the overall strategy for clinical drug product development, supported the development of global regulatory plans, and identified critical opportunities for external collaborations.Dr. Olugemo holds an M.D. from theUniversity of Maryland School of Medicine and aB.Sc . in Clinical Laboratory Science from theUniversity of Massachusetts, Lowell . With her experience in rare and more prevalent diseases,Dr. Olugemo will provide invaluable expertise and leadership to advance Korro’s clinical and regulatory initiatives.
Upcoming Milestones:
- Regulatory filing for KRRO-110 in AATD on track for the second half of 2024.
- Anticipated interim Phase 1/2 clinical trial readout for KRRO-110 in the second half of 2025.
- Completion of the Phase 1/2 clinical trial for KRRO-110 expected in 2026.
First Quarter 2024 Financial Results:
Cash Position: Cash and cash equivalents were
Research and Development (R&D) Expenses: R&D expenses were
General and Administration (G&A) Expenses: G&A expenses were
Net Loss: Korro’s net loss was
About Korro
Korro is a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases using its proprietary RNA editing platform. Korro is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro is expanding the reach of genetic medicines by delivering additional precision and tunability, which has the potential for increased specificity and improved long-term tolerability. Using an oligonucleotide-based approach, Korro expects to bring its medicines to patients by leveraging its proprietary platform with precedented delivery modalities, manufacturing know-how, and established regulatory pathways of approved oligonucleotide drugs. Korro is based in
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, but are not limited to, express or implied statements regarding expectations, hopes, beliefs, intentions or strategies of Korro regarding the future including, without limitation, express or implied statements regarding: Korro’s planned regulatory filing for KRRO-110 in AATD and timing of any interim data readout and completion of any Phase 1/2 clinical trial; Korro’s cash runway; Korro’s ability to advance its pipeline and the role of RNA editing technology in developing therapeutic options; KRRO-110’s potential as a best-in-class drug candidate for AATD; and the benefits of OPERA; among others. In addition, any statements that refer to projections, forecasts, or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “strive,” “would,” “aim,” “target,” “commit,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking. Forward-looking statements are based on current expectations and assumptions that, while considered reasonable are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to, various factors beyond management’s control including risks inherent in biopharmaceutical development; risks associated with pre-clinical studies and clinical trials; and other risks associated with obtaining regulatory approvals and protecting intellectual property; as well as risks associated with general economic conditions; the inability to recognize the anticipated benefits of the merger, which may be affected by, among other things, competition, Korro’s ability to grow and manage growth profitably, maintain relationships with customers and suppliers and retain key employees; costs related to merger; the possibility that Korro may be adversely affected by other economic, business, and/or competitive factors; other risks and uncertainties indicated from time to time in Korro’s filings with the
Korro Contact Information
Investors
IR@korrobio.com
Media
Glenn Silver
FINN Partners
Glenn.silver@finnpartners.com
Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) (unaudited) | |||||||
Three Months Ended | |||||||
2024 | 2023 | ||||||
Operating expenses: | |||||||
Research and development | $ | 13,572 | $ | 14,694 | |||
General and administrative | 7,881 | 5,392 | |||||
Total operating expenses | 21,453 | 20,086 | |||||
Loss from operations | (21,453 | ) | (20,086 | ) | |||
Other income: | |||||||
Other income, net | 1,913 | 481 | |||||
Total other income, net | 1,913 | 481 | |||||
Loss before provision for income taxes | (19,540 | ) | (19,605 | ) | |||
Provision for income taxes | (17 | ) | — | ||||
Net loss and comprehensive loss | $ | (19,557 | ) | $ | (19,605 | ) | |
Net loss per share, basic and diluted | $ | (2.44 | ) | $ | (72.20 | ) | |
Weighted-average shares used in computing net loss per share, basic and diluted | 8,019,626 | 271,522 | |||||
Selected Condensed Consolidated Balance Sheet Data (in thousands) (unaudited) | |||||||
2024 | 2023 | ||||||
Cash, cash equivalents and investments | $ | 138,804 | $ | 166,150 | |||
Working capital (1) | 134,602 | 153,245 | |||||
Total assets | 197,985 | 221,663 | |||||
Total liabilities | 46,627 | 51,752 | |||||
Total stockholders' equity | 151,358 | 169,911 | |||||
(1) Working capital is defined as current assets less current liabilities. | |||||||
Source:
2024 GlobeNewswire, Inc., source